Cayuga Biotech to Present Initial Phase 1 Results of CAY001 at The 2026 ASH Annual Meeting

NEW YORK, NY, UNITED STATES, November 10, 2026 /EINPresswire.com/ -- Cayuga Biotech, Inc., a biotechnology company developing novel therapeutics to address bleeding unmet needs, today announced that initial results from its first-in-human Phase 1 study of CAY001 in healthy volunteers will be presented at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12–15, 2026, in New Orleans, Louisiana.

“We are excited to share the first clinical data from the ongoing phase 1 study of CAY001 in healthy volunteers,” said Andrea Ashford-Hicks, CEO of Cayuga Biotech. “We continue to demonstrate meaningful progress in advancing CAY001 as an acute treatment for life-threatening hemorrhage and the potential of polyP-based therapeutics to address a range of bleeding unmet needs.”

Presentation Details
Title: CAY001, a novel synthetic short-chain polyphosphate–silica nanoparticle complex, shows favorable safety and dose-dependent pro-hemostatic activity in a first-in-human Phase 1a study
Publication Number: 4788
Session Name: 321.Coagulation and Fibrinolysis: Basic and Translational
Session Date & Time: Monday, December 14, 2026 6:00 – 8:00 pm (Central)
Location: Ernest N. Morial Convention Center, Hall F

About CAY001
CAY001 is an investigational single-dose intravenous treatment to address current gaps in care that result in nearly 2 million hemorrhage deaths annually. It accelerates the clotting response specifically at the site of bleeding by mimicking the activity of endogenous platelet polyphosphate (polyP). Its potential as a universal hemostatic drug has been established in preclinical models, demonstrating rapid halt of life-threatening bleeding and the ability to overcome challenging types of coagulation dysfunction.

About Cayuga Biotech, Inc.
Cayuga Biotech is a clinical-stage company developing novel therapeutics to address bleeding unmet needs. Cayuga’s pipeline includes CAY001 (polyP-SNP complex) in development for life-threatening major hemorrhage; CAY002, a discovery-stage program for inherited bleeding disorders, and; a portfolio of additional early-stage programs across the healing continuum. Treatment of bleeding is the first of many therapeutic applications for Cayuga’s proprietary polyP platform. For more information visit www.CayugaBiotech.com.

Disclaimer
This effort sponsored by the Defense Health Agency, Combat Casualty Care Portfolio through the Medical Technology Enterprise Consortium (MTEC) under Other Transaction Number W81XWH-15-9-0001. To find out more about MTEC, visit https://mtec-sc.org/. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

Public Relations
Cayuga Biotech
media@cayugabiotech.com
Visit us on social media:
LinkedIn